# Farah Champsi

> Farah Champsi is a Series A investor at Alta Partners backing Health Care. See 12 investments, round sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Alta Partners](https://shizune.co/investors/profile/alta-partners)
- Location: San Francisco, United States
- Total investments: 12
- Last investment: Dec 2017
- Lead investor: 25%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/farah-champsi-21123066/

Farah Champsi is a Series A investor at Alta Partners in San Francisco focused on Health Care and Biotechnology. Farah Champsi is the Partner at Population Health Partners. She attended Stanford University Graduate School of Business.

## Contacts

5 contacts available for Farah Champsi: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/farah-champsi?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 42% |
| Biotechnology | 4 | 33% |
| Medical | 2 | 17% |
| Biopharma | 2 | 17% |
| Pharmaceutical | 2 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 25% |
| Series B | 2 | 17% |
| Series D | 2 | 17% |
| Series E | 2 | 17% |
| Series C | 1 | 8% |

6 stages tracked in total.

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Allakos | Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatoryresponses. Allakos was founded in 2012 and is headquartered in San Carlos, California. | $100M | Series B | Dec 13, 2017 | https://www.allakos.com/ |
| Allakos | Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatoryresponses. Allakos was founded in 2012 and is headquartered in San Carlos, California. | $10M | Series A | Sep 30, 2014 | https://www.allakos.com/ |
| Allakos | Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatoryresponses. Allakos was founded in 2012 and is headquartered in San Carlos, California. | $24.5M | Series A | Aug 27, 2014 | https://www.allakos.com/ |
| Kite Pharma | Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potentialtherapies could provide novel strategies for the treatment and management of a wide range of tumor types. | $20M | Series A | May 15, 2013 | http://www.kitepharma.com |
| Chimerix | Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs. | $45M | Series F | Feb 14, 2011 | http://www.chimerix.com |
| Trevena | Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines.They have three programs in development:TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas. | $35M | Series B | Jul 14, 2010 | https://www.trevena.com/ |
| Chimerix | Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs. | $16.1M | Series E | Aug 10, 2009 | http://www.chimerix.com |
| Trevena | Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines.They have three programs in development:TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas. | $24M | Series A | Mar 01, 2008 | https://www.trevena.com/ |
| Chimerix | Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs. | $23.1M | Series D | Feb 23, 2007 | http://www.chimerix.com |
| Sanarus Medical | Sanarus Medical, Inc. develops and markets minimally invasive devices for the diagnosis and treatment of breast tumors. It offers Visica treatment system for cryoablation of breast fibroadenomas; Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and ImarC tissue marker system, aline of breast tissue markers that are visible under imaging modalities. The company was founded in 1999 and is headquartered in Pleasanton, California. | $15M | Series E | Feb 20, 2007 | http://www.sanarus.com |

10 of 12 investments shown.

## Co-investors
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 3 deals together
- [Forward Ventures](https://shizune.co/investors/profile/forward-ventures) — VC Fund, 3 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 3 deals together
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 3 deals together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 3 deals together
- Channel Medical Partners — VC Fund, 2 deals together

## About Alta Partners

VC Fund · San Francisco, United States

Alta Partners is a venture capital firm investing in the healthcare and life sciences sector. Their diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for their companies and their investors.

5 contacts available at Alta Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Dan Janney | Managing Director | https://shizune.co/investors/profile/dan-janney |
| Peter Hudson | Managing Director | https://shizune.co/investors/profile/peter-hudson-2 |
| Alison Bord | Director | https://shizune.co/investors/profile/alison-de-bord |
| Bob More | Managing Director | https://shizune.co/investors/profile/bob-more |
| Edward Penhoet | Director | https://shizune.co/investors/profile/ed-penhoet |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Farah Champsi invest in?

Farah Champsi invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Farah Champsi?

Public channels for Farah Champsi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Farah Champsi last invest?

The most recent investment recorded for Farah Champsi closed in Dec 2017. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co